EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ARHGDIB as a prognostic biomarker and modulator of the immunosuppressive microenvironment in glioma

Xuejun Yan, Rongnian Li, Jing Xu, Hua Liu, Minmin He, Xingjun Jiang, Caiping Ren, Quanwei Zhou

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04063-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Xuejun Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Birth Defect for Research and Prevention, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan, China. 421…. Hauptthemen laut MEDLINE: Glioma, Tumor Microenvironment, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Hunan Province, National Natural Science Foundation of China, China Postdoctoral Science Foundation funded project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glioma, a prevalent malignant intracranial tumor, exhibits limited therapeutic efficacy due to its immunosuppressive microenvironment, leading to a poor prognosis for patients. ARHGDIB is implicated in the remodeling of the tumor microenvironment and plays a significant role in the pathogenesis of various tumors. However, its regulatory effect within the immune microenvironment of glioma remains unclear. METHODS: The mRNA expression pattern of ARHGDIB was analyzed using public databases, and its expression was further validated in our collected cohort through quantitative PCR (qPCR) and immunohistochemistry (IHC). Kaplan-Meier survival analysis and LASSO-Cox regression were employed to ascertain the clinical significance of ARHGDIB in glioma. Subsequently, we systematically evaluated the association between ARHGDIB expression and immune characteristics within the glioma microenvironment, as well as its potential to predict treatment response in glioma. Additionally, in vitro experiments were conducted to elucidate the role of ARHGDIB in remodeling the glioma microenvironment and promoting tumor malignancy progression. RESULTS: Combined with bioinformatics analysis of public databases and validation with qPCR and IHC on our cohort, our findings indicate that ARHGDIB is markedly overexpressed in glioma and correlates with poor patient prognosis, thereby serving as a potential biomarker for adverse outcomes in glioma. Functional enrichment and immune infiltration analyses reveal that ARHGDIB is implicated in the recruitment of immunosuppressive cells, such as M2 macrophages and neutrophils, contributing to the alteration of the glioma immunosuppressive microenvironment and hindering the immune response. Further investigations through single-cell sequencing, immunohistochemistry, immunofluorescence, and in vitro experiments demonstrate that ARHGDIB exhibits an expression pattern akin to CD163, with its overexpression inducing M2 macrophage polarization and facilitating glioma cell proliferation and migration. CONCLUSIONS: ARHGDIB emerges as a novel marker for tumor-associated macrophages, playing a crucial role in shaping the immunosuppressive microenvironment and representing a promising prognostic biomarker for glioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaTumor MicroenvironmentBiomarkers, TumorBrain NeoplasmsHumansPrognosisFemaleMaleGene Expression Regulation, NeoplasticTumor-Associated Macrophages

Stichwörter der Autor:innen

ARHGDIBGliomaImmunosuppressive microenvironmentPrognosisTumor-associated macrophages

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • NHC Key Laboratory of Birth Defect for Research and Prevention, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan, China. 421698293@qq.com.
  • Xiangtan Hospital of Traditional Chinese Medicine, Xiangtan, Hunan, China.
  • NHC Key Laboratory of Birth Defect for Research and Prevention, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan, China.
  • Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. jiangxj@csu.edu.cn.
  • The NHC Key Laboratory of Carcinogenesis and The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, School of Basic Medical Science, Central South University, Changsha, China. ren…
  • Department of Neurosurgery, The National Key Clinical Specialty, Zhujiang Hospital, Southern Medical University, Guangzhou, China. 1091040044@qq.com.

Förderung

  • Natural Science Foundation of Hunan Province
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation funded project
  • Guangdong Basic and Applied Basic Research Foundation

Zitieren

APA

Yan, X., Li, R., Xu, J., Liu, H., He, M., Jiang, X., Ren, C., & Zhou, Q. (2025). ARHGDIB as a prognostic biomarker and modulator of the immunosuppressive microenvironment in glioma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04063-7

Vancouver

Yan X, Li R, Xu J, Liu H, He M, Jiang X, et al. ARHGDIB as a prognostic biomarker and modulator of the immunosuppressive microenvironment in glioma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04063-7

BibTeX
@article{Yan2025,
  author = {Yan, Xuejun and Li, Rongnian and Xu, Jing and Liu, Hua and He, Minmin and Jiang, Xingjun and Ren, Caiping and Zhou, Quanwei},
  title = {ARHGDIB as a prognostic biomarker and modulator of the immunosuppressive microenvironment in glioma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04063-7}
}
Kostenlos starten →